Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine

Vaccine. 2002 May 6;20(15):1949-55. doi: 10.1016/s0264-410x(02)00076-2.

Abstract

Heterologous prime/boost regimens have the potential for raising high levels of immune responses. Here, we report that DNA priming followed by a recombinant modified vaccinia Ankara (rMVA) booster has controlled a highly pathogenic immunodeficiency virus challenge in a Rhesus macaque model. Both the DNA and rMVA components of the vaccine expressed multiple immunodeficiency virus proteins. Two DNA inoculations at 0 and 8 weeks and a single rMVA booster at 24 weeks effectively controlled an intrarectal challenge administered 7 months after the booster. These highly promising findings provide hope that a relatively simple multiprotein DNA/MVA vaccine can help to control the AIDS epidemic.

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • AIDS Vaccines / immunology*
  • Animals
  • CD4 Lymphocyte Count
  • Drug Evaluation, Preclinical
  • Immunity, Cellular
  • Immunity, Mucosal
  • Immunization Schedule
  • Immunization, Secondary
  • Immunologic Memory
  • Intestinal Mucosa / immunology*
  • Intestinal Mucosa / virology
  • Lymphocyte Activation
  • Macaca mulatta
  • Rectum
  • Simian Acquired Immunodeficiency Syndrome / prevention & control*
  • Vaccination
  • Vaccines, DNA / immunology*
  • Vaccines, Synthetic / immunology
  • Vaccines, Synthetic / therapeutic use
  • Vaccinia virus / immunology
  • Viral Load
  • Virulence

Substances

  • AIDS Vaccines
  • Vaccines, DNA
  • Vaccines, Synthetic